```html

Kawasaki‑Like Syndrome (Multisystem Inflammatory Syndrome in Children – MIS‑C)

Overview

Multisystem Inflammatory Syndrome in Children (MIS‑C), sometimes described as a “Kawasaki‑like syndrome,” is a rare but serious condition that causes widespread inflammation in multiple organ systems after exposure to the SARS‑CoV‑2 virus (the virus that causes COVID‑19). It typically appears 2–6 weeks after a COVID‑19 infection, even if the initial illness was mild or asymptomatic.

• Who it affects: Primarily children and adolescents ages 0‑21 years, with the highest incidence in those aged 5‑12 years. Both sexes are affected, though slightly more males are reported.
• Prevalence: As of mid‑2024, the CDC estimates ~5,500 MIS‑C cases in the United States since the pandemic began, representing roughly 1 case per 3,000–5,000 SARS‑CoV‑2 infections in kids. Incidence varies by region and by COVID‑19 wave.
• Why “Kawasaki‑like”? Many clinical features (fever, rash, conjunctivitis, mucosal changes, coronary artery involvement) overlap with classic Kawasaki disease, but MIS‑C often presents with more severe cardiac shock, gastrointestinal symptoms, and laboratory markers of cytokine storm.

Understanding MIS‑C is crucial because early recognition and treatment can prevent permanent heart damage and other life‑threatening complications.

Symptoms

Symptoms develop suddenly and persist for at least 24 hours. They can affect many organ systems; the table below groups them by system.

General / Constitutional

• Fever: Persistent high fever (≥38.0 °C / 100.4 °F) lasting > 3 days (most common symptom, seen in > 95% of cases).
• Fatigue, malaise, or feeling “sick”.

Skin & Mucous Membranes

• Diffuse rash (maculopapular, erythematous, or target‑like).
• Red, cracked lips and “strawberry” tongue.
• Conjunctival injection (pink eyes) without discharge.
• Hand/foot swelling or redness; sometimes desquamation (peeling) after 1‑2 weeks.

Cardiovascular

• Chest pain or discomfort.
• Palpitations, tachycardia.
• Low blood pressure or shock (may require fluids/vasopressors).
• Myocarditis, reduced ejection fraction, or coronary artery dilation/aneurysms (similar to Kawasaki disease).

Respiratory

• Shortness of breath or rapid breathing.
• Cough (less common than in acute COVID‑19).

Gastrointestinal

• Abdominal pain, often severe.
• Vomiting and/or diarrhea (present in up to 80% of patients).
• Loss of appetite.

Neurologic

• Headache, confusion, or irritability.
• Seizures (rare but reported).

Laboratory Findings (not symptoms but key clues)

• Elevated inflammatory markers: C‑reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, D‑dimer.
• Neutrophilia, lymphopenia.
• Elevated cardiac enzymes (troponin, BNP/NT‑proBNP).
• Low albumin, high triglycerides, and evidence of coagulopathy.

Causes and Risk Factors

The exact cause of MIS‑C is still under investigation, but current evidence points to an abnormal immune response triggered by prior SARS‑CoV‑2 infection.

• Post‑viral immune dysregulation: The body’s immune system may overreact weeks after viral clearance, leading to a cytokine storm that damages blood vessels and organs.
• Genetic susceptibility: Certain HLA types and polymorphisms in immune‑regulating genes may increase risk, though data are limited.
• Age: Children under 21, especially 5‑12 years, are most vulnerable.
• Sex: Slight male predominance (approximately 1.5:1 male‑to‑female ratio).
• Race/Ethnicity: Higher reported rates among Black, Hispanic, and South Asian children in the U.S. and UK, suggesting possible socioeconomic or genetic influences.
• Previous COVID‑19 infection: Documented positive PCR, antigen test, or serology within the preceding 2‑6 weeks. MIS‑C can also follow asymptomatic infection detected only by antibodies.

Diagnosis

Diagnosing MIS‑C requires a combination of clinical criteria, laboratory evidence, and exclusion of alternative diagnoses (e.g., bacterial sepsis, toxic shock, acute COVID‑19). The CDC and WHO have published working case definitions; the CDC definition (2024) includes:

1. Age < 21 years.
2. Fever ≥ 38 °C for ≥ 24 h.
3. Laboratory evidence of inflammation (elevated CRP, ESR, ferritin, D‑dimer, etc.).
4. ≥ 2 organ systems involved (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurologic).
5. Evidence of current or recent SARS‑CoV‑2 infection (positive PCR/antigen test, or serology) OR known exposure within 4 weeks.
6. Exclusion of alternative plausible diagnoses.

Key Diagnostic Tests

• Blood work: CBC with differential, CRP, ESR, ferritin, D‑dimer, fibrinogen, pro‑BNP/NT‑proBNP, troponin, liver enzymes, kidney function, electrolytes.
• COVID‑19 testing: PCR/antigen (to rule out active infection) and serology (IgG) for prior exposure.
• Echocardiogram: Assess ventricular function, check for coronary artery dilation/aneurysms, pericardial effusion.
• Electrocardiogram (ECG): Look for arrhythmias, ST changes.
• Chest imaging: X‑ray or CT if respiratory symptoms present.
• Abdominal ultrasound/CT: May be ordered for severe abdominal pain to exclude surgical causes.
• Other cultures: Blood, urine, or cerebrospinal fluid cultures if infection is suspected.

Treatment Options

Prompt treatment reduces the risk of cardiac injury and other complications. Management is multidisciplinary (pediatrics, infectious disease, cardiology, rheumatology, intensive care).

First‑line Immunomodulation

• Intravenous Immunoglobulin (IVIG): 2 g/kg given as a single infusion over 8–12 hours. Proven to lower fever and improve cardiac outcomes in Kawasaki disease and MIS‑C.
• Systemic Corticosteroids: Methylprednisolone 1–2 mg/kg/day (IV) or high‑dose pulse (10–30 mg/kg) for refractory cases.

Additional Anti‑inflammatory Agents (for refractory or severe disease)

• Aspirin: High‑dose (30‑50 mg/kg/day) until afebrile for 48 h, then low‑dose (3‑5 mg/kg/day) for antiplatelet effect if coronary changes are present.
• Biologic agents:
  • Infliximab (anti‑TNFα) – used if fever persists after IVIG + steroids.
  • Anakinra (IL‑1 receptor antagonist) – for cytokine storm with high ferritin/D‑dimer.
  • Tocilizumab (IL‑6 inhibitor) – considered in select ICU patients.

Supportive Care

• Fluid resuscitation and vasoactive agents for shock (e.g., norepinephrine, epinephrine).
• Oxygen supplementation or mechanical ventilation if respiratory failure.
• Anticoagulation (low‑molecular‑weight heparin) for markedly elevated D‑dimer or confirmed thrombosis.
• Renal replacement therapy for acute kidney injury.

Follow‑up and Long‑Term Management

• Repeat echocardiograms at 1‑2 weeks, 4‑6 weeks, and 6‑12 months to monitor coronary arteries.
• Cardiology referral for any persistent ventricular dysfunction.
• Gradual tapering of steroids over 2‑4 weeks under physician guidance.
• Vaccination counseling – COVID‑19 vaccination is recommended after recovery (usually ≥ 90 days post‑MIS‑C).

Living with Kawasaki‑Like Syndrome (MIS‑C)

Even after acute recovery, families may face lingering questions and lifestyle adjustments.

Daily Management Tips

1. Medication adherence: Keep a schedule for aspirin, steroids, or any biologics. Use pill boxes or smartphone reminders.
2. Monitor heart health: Watch for chest discomfort, palpitations, or unexplained fatigue. Report any new symptoms to your cardiologist.
3. Balanced activity: Light to moderate exercise is usually safe after doctor clearance. Avoid intense sports until cardiac function normalizes (often 3‑6 months).
4. Nutrition: Focus on anti‑inflammatory foods – fruits, vegetables, omega‑3‑rich fish, whole grains. Stay hydrated, especially if on diuretics or after fluid shifts.
5. School & social life: Most children return to school within 1‑2 weeks if afebrile and stable. Communicate with teachers about any needed accommodations (e.g., rest periods).
6. Psychological support: Hospitalization can be traumatic. Access counseling or support groups for children and families.

Follow‑up Schedule (Typical)

• Week 1‑2: Pediatrician + cardiology visit; labs for inflammatory markers.
• Month 1: Echocardiogram, ECG, and medication review.
• Month 3‑6: Repeat imaging; assessment for tapering steroids.
• Yearly (if coronary changes persist): Ongoing cardiology surveillance.

Prevention

Because MIS‑C follows SARS‑CoV‑2 infection, primary prevention focuses on reducing COVID‑19 transmission and ensuring vaccination.

• COVID‑19 vaccination: Authorized mRNA and protein subunit vaccines for ages 6 months and older have shown > 90% effectiveness at preventing severe disease and appear to lower MIS‑C risk.
• Masking and ventilation: In high‑transmission settings (schools, indoor gatherings), use well‑fitting masks and improve air exchange.
• Hand hygiene & respiratory etiquette: Simple measures still reduce viral spread.
• Testing & isolation: Prompt testing of symptomatic children and quarantine of close contacts curb household transmission.
• Post‑exposure prophylaxis (future): Ongoing trials are evaluating monoclonal antibodies (e.g., tixagevimab‑cilgavimab) for high‑risk pediatric patients; stay informed through your pediatrician.

Complications

If untreated or delayed, MIS‑C can lead to serious, sometimes irreversible problems.

• Coronary artery aneurysms or dilation: Risk of myocardial infarction, thrombosis, or sudden cardiac death.
• Myocardial dysfunction: Heart failure, need for inotropic support, or ventricular assist devices.
• Shock and multi‑organ failure: Acute kidney injury, liver dysfunction, coagulopathy.
• Thromboembolic events: Deep vein thrombosis, pulmonary embolism, stroke.
• Neurologic sequelae: Seizures, encephalopathy, long‑term cognitive changes (rare).
• Psychological impact: Post‑intensive care syndrome (PTSD, anxiety, depression).

Early IVIG and steroids dramatically lower the rate of coronary abnormalities—from ~25% in untreated cases to < 5% with timely therapy (CDC, 2023).

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. MIS‑C Overview. Updated 2024.
• World Health Organization. Multisystem Inflammatory Syndrome in Children. 2023.
• Mayo Clinic. MIS‑C: Symptoms & Causes. Accessed June 2026.
• Cleveland Clinic. MIS‑C Treatment Guidelines. 2024.
• Feldstein LR, et al. “Multisystem inflammatory syndrome in U.S. children and adolescents.” NEJM. 2020;383:334‑346.
• Lopez‐Fernandez L, et al. “Cardiac outcomes after MIS‑C.” JAMA Cardiology. 2023;8(5):432‑440.

```